Cormedics Adds Fontenot to Board
Dr. Billy Cohn Joins Scientific Advisory Board
HOUSTON, June 28, 2012 — Cormedics has appointed healthcare executive and entrepreneur Dr. Mark Fontenot to its Board of Directors, and noted Houston cardiovascular surgeon and medical device inventor Dr. Billy Cohn to the company’s Scientific Advisory Board.
“We are very pleased that these gifted individuals are lending their expertise to Cormedics.” said Jim Meador, Cormedics CEO. “Dr. Fontenot has demonstrated numerous business successes in a spectrum of medical device commercialization ventures, both as an entrepreneur and as an executive. Dr. Cohn is a prolific medical device innovator, and inventor who has already made significant technical contributions to our company,” Meador added.
Dr. Fontenot has been an executive in the healthcare space for over 20 years with extensive entrepreneurial and early stage company experience. He is currently Executive Chairman of OroScience (Palo Alto, CA, specialty pharmaceuticals), and previously was CEO and Chairman of Vascular FX, LLC (Palo Alto, CA; interventional neuroradiology), CEO of Pavier Technologies, LLC (San Jose, CA; interventional vascular therapy), and CEO of Gabriel Medical, Inc. (Lafayette, LA; endoscopic imaging). He has seventeen issued U.S. patents and a number of associated foreign issues and pending domestic and foreign applications.
Dr. Cohn is a cardiovascular surgeon and the Director of Minimally Invasive Surgical Technology at the Texas Heart Institute at St. Luke’s Episcopal Hospital in Houston, Texas. He is the co-director of the Cullen Cardiovascular Research Laboratory and an Associate Professor of Surgery at Baylor College of Medicine and Adjunct Professor of Bioengineering at The University of Houston. Dr. Cohn has more than 40 U.S. patents awarded or pending for his medical innovations and has been honored as the Distinguished Inventor of the Year by the Intellectual Property Owners Association.
Cormedics is an innovative medical device company focused on developing novel and disruptive technologies that selectively treat the entire heart with drug, cell, gene, and device therapies by introduction into the pericardial space. For more information, visit www.CormedicsCorp.com.
About Whole-Heart Therapeutics
Cormedics’ intrapericardial products provide access to the entire epicardial surface of the heart for pericardial effusion, electrophysiology, and cardiac rhythm device therapies. Intrapericardial drug and stem cell delivery may enable preferential targeting of the heart and coronary circulation. The company’s minimally-invasive instrument, the PeriPort, provides access to the pericardial space in order to deliver the targeted therapy. Cormedics has been issued five U.S. patents on intrapericardial therapies, including the PeriPort.
# # #